Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Pfizer Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Mar 30, 2025	Dec 31, 2024	Sep 29, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Oct 1, 2023	Jul 2, 2023	Apr 2, 2023	Dec 31, 2022	Oct 2, 2022	Jul 3, 2022	Apr 3, 2022	Dec 31, 2021	Oct 3, 2021	Jul 4, 2021	Apr 4, 2021	Dec 31, 2020	Sep 27, 2020	Jun 28, 2020	Mar 29, 2020
Short-term borrowings, including current portion of long-term debt	4,470)	6,946)	9,699)	11,944)	8,232)	10,350)	2,548)	3,985)	4,188)	2,945)	4,040)	5,990)	645)	2,241)	3,629)	3,888)	4,352)	2,703)	13,363)	13,084)	16,007)
Trade accounts payable	5,240)	5,633)	5,314)	5,106)	5,591)	6,710)	5,338)	6,081)	6,123)	6,809)	6,267)	6,208)	5,506)	5,578)	4,698)	4,327)	4,064)	4,309)	4,141)	3,872)	3,972)
Dividends payable	—)	2,437)	—)	2,380)	—)	2,372)	—)	2,315)	—)	2,303)	2,245)	2,245)	—)	2,249)	2,191)	2,184)	—)	2,162)	2,112)	2,111)	—)
Income taxes payable	3,105)	2,910)	2,877)	2,884)	3,192)	2,349)	1,898)	2,928)	1,969)	1,587)	3,071)	3,350)	3,177)	1,266)	4,496)	1,742)	1,401)	1,049)	1,430)	1,445)	1,150)
Accrued compensation and related items	2,607)	3,838)	3,383)	2,566)	2,192)	2,776)	2,372)	1,972)	2,277)	3,407)	2,852)	1,997)	2,249)	3,332)	2,571)	2,015)	1,985)	3,058)	2,425)	2,042)	2,246)
Deferred revenues	1,012)	1,511)	2,020)	2,528)	2,502)	2,700)	2,204)	1,286)	1,750)	2,520)	6,191)	3,804)	3,108)	3,067)	3,529)	4,291)	2,052)	1,113)	—)	—)	—)
Other current liabilities	20,018)	19,720)	19,918)	16,411)	18,788)	20,537)	16,776)	16,080)	20,255)	22,567)	19,648)	23,816)	24,583)	24,938)	20,689)	17,217)	12,798)	11,526)	10,683)	10,169)	10,515)
Current liabilities	36,452)	42,995)	43,211)	43,819)	40,497)	47,794)	31,136)	34,647)	36,562)	42,138)	44,314)	47,410)	39,268)	42,671)	41,803)	35,664)	26,652)	25,920)	34,154)	32,723)	33,890)
Long-term debt, excluding current portion	57,639)	57,405)	58,002)	57,506)	61,307)	61,538)	61,048)	61,356)	31,704)	32,884)	32,629)	34,294)	35,656)	36,195)	36,250)	35,354)	35,347)	37,133)	49,785)	50,529)	36,281)
Pension and postretirement benefit obligations	2,021)	2,115)	2,073)	2,040)	2,076)	2,167)	2,166)	2,184)	2,179)	2,250)	2,960)	3,257)	3,494)	3,724)	4,303)	4,939)	5,161)	5,411)	6,437)	6,430)	6,535)
Noncurrent deferred tax liabilities	2,258)	2,122)	2,158)	2,227)	931)	640)	1,125)	1,232)	1,067)	1,023)	616)	558)	655)	349)	328)	4,161)	4,355)	4,063)	4,542)	5,409)	5,268)
Other taxes payable	5,724)	6,112)	5,905)	6,532)	8,603)	8,534)	8,099)	8,052)	9,860)	9,812)	9,701)	10,990)	11,574)	11,331)	11,336)	11,259)	11,759)	11,560)	11,720)	11,468)	12,212)
Other noncurrent liabilities	13,297)	14,150)	15,569)	16,094)	15,123)	16,540)	14,243)	13,404)	13,009)	13,181)	12,239)	11,312)	10,508)	9,743)	9,201)	8,228)	6,679)	6,669)	6,849)	6,811)	6,812)
Noncurrent liabilities	80,939)	81,904)	83,707)	84,399)	88,040)	89,419)	86,681)	86,228)	57,819)	59,150)	58,145)	60,411)	61,887)	61,342)	61,418)	63,941)	63,301)	64,836)	79,333)	80,647)	67,108)
Total liabilities	117,391)	124,899)	126,918)	128,218)	128,537)	137,213)	117,817)	120,875)	94,381)	101,288)	102,459)	107,821)	101,155)	104,013)	103,221)	99,605)	89,953)	90,756)	113,487)	113,370)	100,998)
Preferred stock	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	17)
Common stock	481)	480)	480)	480)	480)	478)	478)	478)	478)	476)	476)	476)	476)	473)	473)	472)	472)	470)	470)	471)	470)
Additional paid-in capital	93,856)	93,603)	93,477)	93,197)	92,997)	92,631)	92,496)	92,329)	92,153)	91,802)	91,359)	91,183)	90,844)	90,591)	89,973)	89,336)	89,002)	88,674)	88,161)	87,886)	87,680)
Treasury stock	(115,008)	(114,763)	(114,760)	(114,757)	(114,755)	(114,487)	(114,485)	(114,482)	(114,473)	(113,969)	(113,945)	(113,939)	(113,932)	(111,360)	(111,358)	(111,354)	(111,348)	(110,988)	(110,980)	(110,978)	(111,010)
Retained earnings	119,590)	116,725)	121,060)	116,596)	121,318)	118,353)	126,411)	128,796)	131,101)	125,656)	122,966)	116,607)	111,193)	103,394)	102,252)	96,346)	95,158)	96,770)	100,284)	100,203)	101,000)
Accumulated other comprehensive loss	(8,581)	(7,842)	(7,971)	(7,816)	(7,758)	(7,961)	(7,966)	(8,102)	(8,289)	(8,304)	(8,225)	(7,119)	(6,157)	(5,897)	(5,649)	(4,758)	(4,664)	(11,688)	(12,676)	(13,246)	(13,131)
Total Pfizer Inc. shareholders’ equity	90,338)	88,203)	92,286)	87,700)	92,282)	89,014)	96,934)	99,019)	100,970)	95,661)	92,631)	87,208)	82,424)	77,201)	75,691)	70,042)	68,620)	63,238)	65,259)	64,336)	65,026)
Equity attributable to noncontrolling interests	299)	294)	272)	275)	276)	274)	270)	274)	266)	255)	260)	261)	261)	261)	276)	273)	245)	235)	236)	228)	312)
Total equity	90,637)	88,497)	92,558)	87,975)	92,558)	89,288)	97,204)	99,293)	101,236)	95,916)	92,891)	87,469)	82,685)	77,462)	75,967)	70,315)	68,865)	63,473)	65,495)	64,564)	65,338)
Total liabilities and equity	208,028)	213,396)	219,476)	216,193)	221,095)	226,501)	215,021)	220,168)	195,617)	197,204)	195,350)	195,290)	183,840)	181,475)	179,188)	169,920)	158,818)	154,229)	178,982)	177,934)	166,336)

Short-term borrowings, including current portion of long-term debt: Short-term borrowings showed volatility over the periods, with an initial decrease from $16,007 million in March 2020 to $2,703 million in December 2020, followed by a rise and fluctuations thereafter. Notably, there was a peak at $10,350 million in March 2024 before declining to $4,470 million by March 2025.
Trade accounts payable: Trade accounts payable generally increased from $3,972 million in March 2020 to a peak of $6,809 million in December 2022. Thereafter, it declined gradually to $5,240 million by March 2025, indicating some reduction in outstanding payables towards suppliers.
Dividends payable: Dividends payable remained relatively stable, mostly fluctuating around $2,100 to $2,400 million. There was some missing data, but values indicate a consistent dividends commitment throughout the periods.
Income taxes payable: Income taxes payable experienced fluctuations with a significant spike to $4,496 million in October 2021 from lower amounts around $1,000-$1,700 million beforehand. Subsequently, it varied sharply, ending at $3,105 million in March 2025, reflecting variability in tax liabilities or payment timing.
Accrued compensation and related items: This liability showed oscillations, starting at $2,246 million in March 2020, peaking at $3,838 million in March 2025. The trend indicates increasing accrued employee-related costs especially towards the later periods.
Deferred revenues: Deferred revenues data was partly missing initially. When reported, it rose substantially between 2021 and 2022, reaching a high of $6,191 million in October 2022, before declining steadily to $1,012 million by March 2025, suggesting changes in advance payments or services yet to be delivered.
Other current liabilities: Other current liabilities grew consistently from $10,515 million in March 2020 to a peak around $24,938 million in December 2021, followed by fluctuations and a decrease to approximately $20,018 million by March 2025, indicating variability in short-term obligations not specifically categorized.
Current liabilities: Overall current liabilities showed an increase from $33,890 million in March 2020 reaching a peak of $47,794 million in December 2023. Fluctuations occurred afterward, ending at $36,452 million in March 2025, impacted by the movements in components like short-term borrowings and other liabilities.
Long-term debt, excluding current portion: Long-term debt exhibited notable volatility. Starting at $36,281 million in March 2020, it increased markedly to $61,356 million by July 2023, maintaining levels near $57,000-$61,000 million thereafter, indicating significant debt raises particularly in mid-2023.
Pension and postretirement benefit obligations: These obligations steadily declined from $6,535 million in March 2020 to around $2,021 million by March 2025, suggesting reductions in pension liabilities or changes in actuarial assumptions over time.
Noncurrent deferred tax liabilities: Noncurrent deferred tax liabilities decreased from $5,268 million in March 2020 to a low of $328 million in October 2021, followed by moderate increases totaling $2,258 million by March 2025, showing considerable changes in deferred tax positions.
Other taxes payable: Other taxes payable trended downward from $12,212 million in March 2020 to $5,724 million in March 2025, reflecting a reduction in certain tax-related obligations over the period.
Other noncurrent liabilities: Other noncurrent liabilities increased from $6,812 million in March 2020 to a peak of $16,540 million in December 2023, followed by a moderate decrease to $13,297 million in March 2025, signaling growing long-term liabilities beyond pensions and debt.
Noncurrent liabilities: Noncurrent liabilities rose from $67,108 million in March 2020 to a peak near $86,681 million in July 2023, thereafter declining gradually to $80,939 million by March 2025, mainly driven by increases in long-term debt and other noncurrent obligations.
Total liabilities: Total liabilities fluctuated, increasing from $100,998 million in March 2020 to a high of $137,213 million in December 2023, then falling to $117,391 million by March 2025, reflecting changes in both current and noncurrent liabilities.
Preferred stock: Preferred stock presence was minimal or non-existent after March 2020 and remained largely unreported in subsequent periods.
Common stock: Common stock value showed a gradual increase from $470 million in March 2020 to $481 million in March 2025, reflecting slight changes likely due to issuance or adjustments.
Additional paid-in capital: Additional paid-in capital consistently increased over the timeline from $87,680 million in March 2020 to $93,856 million in March 2025, indicating ongoing equity financing or capital transactions.
Treasury stock: Treasury stock values became more negative over time, moving from -$111,010 million in March 2020 to -$115,008 million in March 2025, reflecting increased repurchases or adjustments in treasury holdings.
Retained earnings: Retained earnings showed overall growth, increasing from $101,000 million in March 2020 to a peak near $131,101 million in April 2023. Slight fluctuations and declines followed, ending at $119,590 million in March 2025, indicating accumulation of earnings net of dividends.
Accumulated other comprehensive loss: The accumulated other comprehensive loss decreased in absolute terms from -$13,131 million in March 2020 to near -$7,966 million in October 2023, before varying slightly and ending at -$8,581 million in March 2025, suggesting some reduction in negative comprehensive items.
Total Pfizer Inc. shareholders’ equity: Shareholders’ equity increased from $65,026 million in March 2020 to a peak of about $101,236 million in April 2023, followed by a decline to $90,338 million by March 2025, showing growth in equity capital then some contraction, potentially influenced by net income, dividends, and treasury stock transactions.
Equity attributable to noncontrolling interests: This component remained relatively stable with a slight upward trend from $312 million in March 2020 to $299 million in March 2025, indicating minor changes in noncontrolling interest ownership.
Total equity: Total equity tracked similarly to shareholders’ equity, growing from $65,338 million in March 2020 to $101,236 million in April 2023, then declining to $90,637 million in March 2025, reflecting overall equity position changes.
Total liabilities and equity: The combined total of liabilities and equity rose from $166,336 million in March 2020 to a peak of $226,501 million in December 2023, before decreasing to $208,028 million by March 2025, indicating growth in the company's balance sheet total followed by a moderate contraction.

Download chart

Pfizer Inc. (NYSE:PFE)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data